Sclerotium rolfsii lectin (SRL) is a lectin isolated from fungus S. rolfsii and has high binding specificity toward the oncofetal Thomsen-Friedenreich carbohydrate antigen (Galβ1-3GalNAc-α-O-Ser/ Thr, T or TF), which is expressed in more than 90% of human cancers. Our previous studies have shown that binding of SRL to human colon, breast and ovarian cancer cells induces cell apoptosis in vitro and suppresses tumor growth in vivo. This study investigated the SRL-mediated cell signaling in human colon cancer HT29 cells by mRNA and miRNA microarrays. It was found that SRL treatment results in altered expression of several hundred molecules including mitogen-activated protein kinase (MAPK) and c-JUN-associated, apoptosis-associated and cell cycle and DNA replication-associated signaling molecules. Pathway analysis using GeneSpring 12.6.1 revealed that SRL treatment induces changes of MAPK and c-JUN-associated signaling pathways as early as 2 h while changes of cell cycle, DNA replication and apoptosis pathways were significantly affected only after 24 h. A significant change of cell miRNA expression was also observed after 12 h treatment of the cells with SRL. These changes were further validated by quantitative real time polymerase chain reaction and immunoblotting. This study thus suggests that the presence of SRL affects multiple signaling pathways in cancer cells with early effects on cell proliferation pathways associated with MAPK and c-JUN, followed by miRNA-associated cell activity and apoptosis. This provides insight information into the molecular mechanism of the anticancer activity of this fungal lectin.
Introduction
Glycans expressed on cell surface are increasingly implicated in cellcell, cell-extracellular interactions and in transducing the signals required for normal cell growth (Ohtsubo and Marth 2006) . Studies have shown that these glycans are often altered during various pathophysiological conditions and these altered glycosylation is correlated with malignant transformation and metastasis in human cancer (Ono and Hakomori 2004; Dube and Bertozzi 2005) . Truncated expression of O-glycans particularly Tn (GalNAc-α-O-Ser/Thr), sialyl-Tn (Neu5Acα2-3GalNAcα-O-Ser/Thr) and TF (Galβ1-3Gal-NAc-α-O-Ser/Thr, T or TF) antigens reported in different human tumors is correlated with tumor progression and metastasis (Tuccillo et al. 2014) . The altered glycans can be recognized by glycan binding proteins (GBP) or tumor-specific lectins. Cancer is a complex genetic disease with multiple tumor subclasses, which are difficult to classify and diagnose with methods that are based on clinical and morphologic features that only partially reflect tumor heterogeneity (Bertucci et al. 2003) . In recent years, these limitations are being addressed using microarray technology that allows studying the changes in transcriptome at cellular level and gives expression profiles of genes among different tumor subclasses at once and hence facilitates identification of this tumor heterogeneity.
In this context lectins are emerging as new anticancer drugs (Jiang et al. 2015) . Lectins are naturally occurring multivalent carbohydrate binding proteins, some of which can detect cancer-associated glycans and therefore have the potential to serve as biomarkers for malignant tumors and to assist in the study of changes in the glycosylation motif in cancer cell lines (Mody et al. 1995; Madariaga et al. 2014) . Some lectins have been identified and developed as useful markers of proliferation, differentiation and malignant transformation in the human colon (Boland et al. 1992) . Lectins are also valuable tools for the enrichment of glycoproteins from a complex sample, facilitating the discovery of novel cancer biomarkers (Clark and Mao 2012) . The unique property of lectins has been exploited for blood typing, fractionation of animal cells, as taxanomic markers for identification and differentiation of various microorganisms and in cell sorting (Guillot and Konska 1997; Khan and Khan 2011) .
Many lectins are also known for exerting diverse physiological responses like mitogenic, cytotoxic, antiproliferative, apoptotic or immunomodulatory effects against human cancer cells and hence are gaining recognition in cancer biology both as diagnostic and therapeutic agents (Khan and Khan 2011; Eligar et al. 2013) . This is particularly true for lectins recognizing oncofetal Thomsen-Friedenreich antigen (Galβ1-3GalNAc-α-O-Ser/Thr, T or TF), which is expressed in more than 90% of human cancers including colon cancer and expression of TF is correlated with tumor progression and metastasis (Yu 2007) . TF antigen-specific lectins like Agaricus bisporus (ABL) and Artocarpus integrifolia ( jacalin) are shown to inhibit proliferation of human colon cancer cells in reversible ways (Yu et al. 1993; Kabir 1998) , in contrast lectins from Amarantus caudatus (ACA) and Arachis hypogea (Peanut agglutinin) induce cell proliferation (Yu et al. 2001 ) by using diverse signaling mechanism.
MicroRNAs (miRNAs) are non-coding RNAs that are known to regulate gene expression at transcriptional and post-transcriptional levels. Recent studies have shown the significance of miRNAs in regulating cancer metastasis by acting as tumor suppressors and oncogenes (Ahmad et al. 2013) . mRNA and miRNA microarray techniques are of significance not only in providing new molecular markers in cancer that could be used in diagnosis and prognosis (van't Veer et al. 2002; Bertucci et al. 2003; 2004) , but also to develop targeted anticancer drugs. Most of anticancer agents do not differentiate between cancerous and normal cells, and hence are known to cause disastrous toxicity and have reduced efficiency. Hence there is always a need for the development of innovative drugs that selectively target cancer cells while sparing normal tissues and also which can differentiate different tumor subclasses. Understanding the molecular mechanism of action of novel molecules with potential to be developed as anticancer drugs by the genomics approach not only helps in identifying new diagnostic markers but also enhances therapeutic efficiency of novel molecules.
We have earlier reported TF antigen-specific Sclerotium rolfsii lectin (SRL) from a soil-borne plant pathogenic fungus Sclerotium rolfsii that is involved in development and morphogenesis of fungus (Swamy et al. 2001 (Swamy et al. , 2004 . Structure of SRL has been reported at 1.1 A°reso-lution, and glycan array analysis revealed the exquisite binding affinity of SRL not only to TF antigen but also to TF associated O-linked glycans (Leonidas et al. 2007; Chachadi et al. 2011) . SRL inhibits the growth of human colon cancer HT29, DLD-1, ovarian cancer PA-1 and breast cancer MCF-7 cells in vitro by induction of cellular apoptosis involving both extrinsic and intrinsic signaling pathways and suppresses tumor growth in vivo in NOD-SCID mice bearing HT29 xenografts Inamdar et al. 2012; Savanur et al. 2014) . In this study, we investigated SRL-mediated singaling pathways in human colon cancer HT29 cells using global microarray analysis to understand the molecular mechanism of the anticancer activity of this lectin, SRL.
Results

SRL binding to HT29 cells is inhibited by the presence of TF-expressing glycans
SRL binding to human colon epithelial cancer HT29 cells was assessed by flow cytometry using FITC conjugated SRL in the presence and absence of bovine asialo mucin (BAM) and bovine mucin (BM). SRL showed strong binding to HT29 cells with mean fluorescence intensity of 226 ( Figure 1A ) whereas presence of BAM and BM showed to inhibit SRL binding to HT29 cells by 98.69 and 97.96%, respectively. This suggests that SRL binding to the cells is mediated through its carbohydrate binding site. FITC conjugated bovine serum albumin (FITC-BSA) was included as a control to check the cell surface binding, and it showed no binding to HT29 cells.
SRL inhibits cells growth
HT29 cells treated with SRL showed time-dependent growth inhibition marginally at early time points (2, 4, 8 and 12 h) . SRL at 20 µg/mL caused 7.47 ± 2.22, 8.21 ± 0.70, 10.05 ± 0.62 and 12.93 ± 0.14% cell growth inhibition after 2, 4, 8 and 12 h, respectively (Figure 1B) . SRL at 20 µg/mL induced significant cell growth inhibition in a time-dependent manner at late time points (24 and 48 h). SRL at 24 and 48 h caused 22.88 ± 0.61 and 47.01 ± 2.14% growth inhibition, respectively, in HT29 cells ( Figure 1C) .
The inhibitory effect of SRL on HT29 cells was blocked by the presence of TF-expressing BAM and BM (100 µg/mL) by 66.71 and 77.95%, respectively ( Figure 1D ).
SRL alters gene expressions
In our previous studies, SRL at a concentration of 20 µg/mL has shown to produce maximum cell growth inhibition, hence we have selected this concentration for studying global gene expression profiling in HT29 cells . HT29 cells treated with SRL at different time points (early and late time points) revealed differential expression of several genes as compared with untreated control cells (Supplementary data, SI-2 for late time points). A total of 366, 542, 684, 918, 1781 and 6566 entities were differentially regulated at 2, 4, 8, 12, 24 and 48 h, respectively, following SRL treatment. Pathway analysis was carried out using differentially expressed genes (DEGs) on Single Experiment Analysis (SEA) option of GeneSpring GX 12.6.1 software. The differentially regulated gene list following lectin treatment was used to identify pathways affected at various time points. The major pathways affected at early time points were mitogen-activated protein kinase (MAPK), insulin and transforming growth factor beta (TGFβ) and DNA damage signaling pathways (Heat map for TGFβ (SI-3) and DNA damage (SI-4) signaling pathways is provided as Supplementary data), whereas at late time points of 24 and 48 h post-SRL treatment, cell cycle, DNA replication and apoptosis signaling pathways were affected most significantly.
SRL affects MAPK and insulin signaling pathways at early time points
MAPKs transmit the extracellular signals and control fundamental cellular processes such as growth, proliferation, differentiation, migration and apoptosis. Several MAPK genes showed noticeable differential regulation at early time points (Table I and Figure 2) . The transcription factor c-JUN showed 10-fold up-regulation as early as 2 and 4 h following lectin treatment with the expression level gradually decreasing to 3.51 and 2.62 fold, respectively, at 8 and 12 h. c-JUN was the common MAPK gene to be up-regulated at all the early time points (Figure 3 ). MAP3K5 was down-regulated at all the early time points except at 2 h. At 2 h post-SRL treatment, MAP3K14 and DUSP1 were up-regulated and MAP3K4 and ATF2 were downregulated. At 4 h post-SRL treatment, transmembrane receptor Fas showed a marked up-regulation while MAPK6, KRAS and ELK1 were down-regulated. MAPK signaling genes like TMEM37, PDGFB, TGFβR2 and DUSP10 were down-regulated at 8 h post-SRL treatment. At 12 h post-SRL treatment, EGFR, DDIT3 and MEF2C were up-regulated and MAPK6, MAP3K5 and TGFβR2 were downregulated.
One of the other key pathways significantly affected at early time points upon SRL treatment is the insulin signaling pathway. Differentially regulated insulin pathway genes are presented in Table II . c-JUN and SOCS1 were the common up-regulated genes at early time points. SOCS1 was up-regulated with the fold change of 2, 3.8, 3.3 and 3.3 at 2, 4, 8 and 12 h, respectively. At 2 h post-SRL treatment, EGR1 was up-regulated and FOXO1A and ELK1 were down-regulated. At 4 h, IRS2 was up-regulated and IGF1R, IRS1, PIK3CB, ELK1 and MAPK6 were down-regulated by SRL. At 8 and 12 h, IGF1R, IRS1 and EGR1 and MAPK6 were down-regulated by SRL, respectively. Fig. 1 . Binding of FITC-SRL and effect of SRL on HT29 cell growth. Human colon epithelial cancer HT29 cells were incubated with FITC-SRL (2 µg/mL) in the presence or absence of competing glycoconjugates (100 µg/mL), with FITC-BSA (2 µg/mL) and binding was analyzed by flow cytometry. Overlays are representative data, with X-axis and Y-axis representing fluorescence intensity and cell events, respectively A. SRL at 20 µg/mL was incubated with HT29 cells for early (2, 4, 8 and 12 h) B and late time points (24 and 48 h) C. Cell viability after each time point was measured by Calcein AM assay. HT29 cells were incubated with DSRL (20 µg/mL) and TBS for late time points and viability was analyzed C. HT29 cells were incubated in the absence or presence of SRL (20 µg/mL) with or without BAM and BM (100 µg/mL) and cell viability was analyzed by Calcein AM assay after 48 h D. This figure is available in black and white in print and in color at Glycobiology online.
SRL affects cell cycle and DNA replication pathways at late time points (24 and 48 h)
Several genes involved in cell cycle, DNA replication and apoptosis pathways were significantly affected at 24 h by lectin, suggesting that the initial signaling cascades lead to the disruption of cell cycle impairment of DNA replication process and induction of apoptosis. SRL down-regulated KITLG, SKP2, MDM2, SMC1A, ESPL1, CHEK2, PCNA, CDC25A, CDC25B, CDC25C, PLK1, MCM2, MCM5, MCM6, MCM7, ORC1, ORC2, ORC5, RBL1 and E2F2 genes belonging to cell cycle ( Figure 4 and Table III ). The only gene in this pathway that was found to be up-regulated by SRL was CDC14A.
SRL treatment also down-regulated DNA replication pathway genes like CDT1, POLA2, PRIM2, RPA1, RPA4, RPA2, POLE2, RFC2, PCNA, POLD1 and POLD3 excluding RPA4, which was the only gene up-regulated ( Figure 5 and Table IV ). All these genes play an essential role in the regulation of cell survival and proliferation.
SRL affects apoptosis signaling pathway at late time points (24 and 48 h) Apoptosis was the major signaling pathway affected by SRL both at 24 and 48 h. At 24 h, SRL induced altered expression of apoptosis pathway genes like BMF, BCL2-interacting killer (BIK), TNFR11B, BIRC2 and MNTRN2L10 that were up-regulated and DFFB, CYC1 and CYCS that were down-regulated ( Figure 6A and Table V) . SRL continued to induce the altered expression of apoptosis pathway genes at 48 h as evidenced by the up-regulation of apoptosis genes like FasLG, Harakiri (HRK), BMF, SEPT4, BIRC2, MAPK8 and NOXA and down-regulation of CASP3, MAP3K5, PTRH2, CRADD, PIDD and BH3 interacting domain (BID) ( Figure 6B and Table VI) .
SRL differentially regulates miRNAs expression
To identify the miRNA candidates affecting gene expression, miRNA microarrays was performed on SRL-treated and untreated HT29 cells at various time points. At 2 and 4 h, eight and seven miRNAs were differentially regulated, respectively, with the number of miRNAs increasing significantly post-4 h of lectin treatment. At 8 and 12 h, 85 and 144 miRNAs were differentially expressed, respectively, between the treated and control samples (P ≤ 0.05). These 85 and 144 miRNA targets 1871 and 2065 validated and reported genes out of which 33 and 31 genes overlap with differential expressed genes following lectin treatment.
The number of differentially regulated miRNAs decreased significantly post-12 h of lectin treatment with 52 (28 up and 24 down) and 19 (8 up and 11 down) miRNAs being detected at 24 and 48 h, respectively. Comparison of the validated targets of these miRNAs with the differential gene expression list revealed overlap of ∼81 and 19 genes at 24 and 48 h, respectively (Supplementary data SI-2). Pathway analysis performed with the 81 validated target genes identified at 24 h revealed that the differentially regulated miRNAs at 24 h controlled genes mostly belonging to the cell cycle pathway (7 genes out of 81) ( Figure 7 ).
Validation of microarray analysis with qReal-time-PCR and western blotting
The gene expression microarray data were compared and validated with quantitative real time polymerase chain reaction (qRT-PCR). Seventeen genes up-and down-regulated from early time points ( Figure 8A ) and eight genes from late time points ( Figure 8B ) were chosen for the purpose (Table VII) .
To validate the observed results from gene expression studies, key genes differentially regulated from each of the significantly affected pathway following lectin treatment were selected for monitoring their expression by western blotting analysis. The expression of proteins like c-JUN from MAPK pathway, PLK1 and Cyclin D1 from cell cycle pathway, respectively, and RPA4 from DNA replication pathway were monitored.
SRL treatment totally diminished expression of c-JUN at all the early time points ( Figure 9A ), however, only a slight expression of c-JUN was observed at 4 h, which is much less compared with the control. SRL treatment totally abolished the expression of cell cycle protein PLK1 at 24 and 48 h, and the lectin partially down-regulated expression of cyclinD1 at 48 h. However, no change in expression of RPA4 was seen in SRL-treated samples at late time points ( Figure 9B ). 
Discussion
In this study, we report the global gene expression and signaling pathways affected by the antitumor lectin SRL in human colon cancer HT29 cells by mRNA and miRNA microarray analysis. It demonstrated that SRL differentially regulated genes associated with MAPK, c-JUN, cell cycle, DNA replication and apoptosis signaling pathways at various time points. This is further confirmed by qRT-PCR and western blotting analysis.
Our previous studies have shown that SRL induces cell apoptosis and inhibits cell growth in human colon cancer HT29 cells in vitro and suppresses tumor growth in NOD-SCID mice bearing HT29 xenografts in vivo . SRL also strongly inhibits the growth of human breast cancer MCF-7 and ZR-75 cells, whereas it has only weak effect on normal epithelial nontumorigenic MCF-10A cells and human mammary epithelial cells, HMECs suggesting that SRL has minimal effect on growth of human normal epithelial cells compared with cancer cells (Savanur et al. 2014) . In this gene profiling study using GeneSpring GX 12.6.1 software has shown that the . Cell cycle pathway is significantly affected at 24 h. Cell cycle genes like KITLG, SKP2, MDM2, SMC1A, ESPL1, CHEK2, PCNA, CDC25A, CDC25B, CDC25C, PLK1, MCM2, MCM5, MCM6, MCM7, ORC1, ORC2, ORC5, RBL1 and E2F2 were down-regulated by SRL. The expression levels of the genes at various time points as depicted by the heat strips are in the order of 0 h C, 24 h C, 24 h T, 48 h C and 48 h T. This figure is available in black and white in print and in color at Glycobiology online.
presence of SRL affected MAPK, insulin, TGFβ and DNA damage signaling pathways at 2, 4, 8 and 12 h. Whereas at 24 h, the lectin most significantly affected cell cycle and DNA replication signaling pathways. Changes of apoptosis signaling pathway was also observed after 24 and 48 h SRL treatment. Global gene profiling studies facilitates to monitor the mechanism of action of drugs on cancer cell lines at molecular level and also provides information on differentially regulated genes, which may be either up-or down-regulated. In general, it is difficult to analyze and interpret complex gene expression data and to derive a proper conclusion. Up-regulation of a particular gene not always results in increased expression of the corresponding protein because of complex posttranscriptional and translational/post-translational regulations. On the other hand, when a gene is down-regulated it is always correlated with the down-regulation of the corresponding protein (Al Moustafa et al. 2002; Chuaqui et al. 2002) hence down-regulated genes identified can be used as authenticated data to hypothesize/predict the molecular mechanism of any drug action on cancer cells. Considering this, we have focused mainly on SRL-induced down-regulated genes in HT29 cells to analyze and interpret the data and to derive the meaning full conclusion.
SRL affected MAPK and insulin pathway genes at early time points. MAPK is affected as early as 2 h in HT29 cells and the lectin down-regulated transcripts of MAP3K4 and ATF2. Mitogen-activated protein kinase kinase kinase 4 (MAP3K4) activates specifically the c-Jun N-terminal Kinase (JNK) pathway, which is implicated in tumorogenesis and neurogenerative disorders. MEKK4 and activating transcription factor 2 (ATF2) have been implicated in both tumor promoting and tumor suppressing in various cancers (Davies and Tournier 2012; Lau and Ronai 2012) . Apoptosis signal regulating kinase 1; ASK1/MAP3K5 is down-regulated at all early time points except at 2 h, which regulates reactive oxygen species (ROS) and apoptosis (Ichijo et al. 1997) . At 4 h, SRL down-regulated transcripts of KRAS and ELK1. KRAS reported to be mutated in colorectal cancer (CRC) and is associated with continuous activation of proliferation signal (Phipps et al. 2013) . The transcription factor ELK-1 is a key regulator of immediate-early genes, implicated in tumor promoting effect and blocking apoptotic cell death in many tumors (Zhang et al. 2007) . At 8 h, SRL down-regulates platelet-derived growth factor beta polypeptide (PDGFB) and TGFβR2, which are implicated in cell proliferation, survival and metastasis. Furthermore in vivo studies have shown that inhibition of TGF-β signaling inhibits tumor metastasis (Andrae et al. 2008; Ostapoff et al. 2012) . Another gene down-regulated at 8 h by SRL is DUSP 10, which is known to inactivate JNK and p38 pathway and its increased expression is correlated with the malignant phenotype of colon tumors (Nomura et al. 2012) .
SRL also differentially regulated genes belonging to insulin pathway at early time points. Some of the genes down-regulated were common to both MAPK and insulin pathway namely, ELK1 and MAPK6. Early growth response 1 (EGR1) was up-regulated and downregulated at 2 and 8 h, respectively, and it has been implicated both in tumor suppression or tumor promotion depending on the cell type (Krones-Herzig et al. 2005) . Another important gene downregulated by SRL is PIK3CB (Phosphoinositide-3-Kinase, Catalytic, Beta Polypeptide), implicated in colon cancer growth and downregulation of PIK3CB protein levels shown to inhibit growth of colon cancer (Li and Yu-gang 2011) . Other two insulin pathway genes IRS1 and IGF1R are down-regulated by SRL at 4 and 8 h and are known to promote tumorogenesis and metastasis. Tumor promoting role of IGFR1 is implicated in several cancers and is correlated with drugs and radiotherapy resistance acquired by cancer cells (Jones et al. 2004; Warshamana-Greene et al. 2005) . IGF/IGF1R inhibitors are being used in targeting the IGF pathway; some are already in clinical trials (Chen and Sharon 2013).
Taken together, at early time points, SRL down-regulates important MAPK and insulin pathway genes, which are implicated for their tumor promoting role and hence supports the observed anticancer effect of SRL in HT29 cells.
SRL at late time points mainly affected pathways belonging to cell division and replication viz. cell cycle and DNA replication pathways. Cell cycle pathway is critical for cell survival and is tightly regulated by two class of proteins namely cyclin dependent kinases (CDKs) and cyclins (King and Cidlowski 1998) . At 24 h, SRL down-regulated cell cycle genes involved in different phases namely, SCF, SKP2, E2F2 and RBL1 were down-regulated in G1 phase, MDM2, PCNA, ORC1, ORC2, ORC5, CDC25A, MCM2, MCM5, MCM6 and MCM7 were down-regulated in S phase and PLK1, CHEK2, CDC25B, CDC25C, SMC1A and ESPL1 were down-regulated in G2/M phase. CDC14A is the only gene up-regulated by lectin in cell cycle pathway belonging to G2/M phase. SCF-Skp2, F-box-protein-bound SCF complex, promotes cell cycle progression and growth (Nakayama and Nakayama 2005; Frescas and Pagano 2008) . Skp2 overexpression is implicated in human cancer progression and metastasis and its deficiency is shown to inhibit cancer development. Hence targeting SCF-Skp2 is considered as a novel target for cancer therapeutics (Chan et al. 2010 (Chan et al. , 2012 . Transcription factor E2F2 regulates cell cycle progression, apoptosis, DNA repair and differentiation and is a target of transcription factor Myc and is essential for Myc-induced cell proliferation but not for Myc-induced apoptosis (Leone et al. 2001) .
Origin recognition complex (ORC) proteins are significantly down-regulated upon SRL treatment, which promotes the initiation of DNA replication (Duncker et al. 2009 ). SRL also down-regulated MCM2, MCM5, MCM6 and MCM7, which are essential for DNA replication. Overexpression of MCM 2, 4, 5, 6 and 7 proteins is reported in promoting cervical carcinogenesis ). Overexpression of MCM-7 is considered as a prognostic factor in human colorectal cancer metastases (Nishihara et al. 2008 ). The murine double minute 2 (MDM2) is E3 ubiquitin ligase and inhibitor of tumor suppressor p53. Overexpression of MDM2 is observed in ∼10% of human cancer (Iwakuma and Lozano 2003) . Inhibiting the MDM2-p53 interaction has been suggested as a strategy to combat tumorogenesis (Zak et al. 2013) . Proliferating cell nuclear antigen (PCNA), a biomarker of colorectal adenocarcinoma, is often overexpressed in cancer cells (Guzinska-Ustymowicz et al. 2009 ) and is essential for DNA replication and repair, which is down-regulated by SRL.
A number of phosphatases involved in cell cycle progression are also down-regulated by SRL. Elevated expression of Cdc25A, S phase dual specificity phosphatase is correlated with promoting colon carcinogenesis (Dixon et al. 1998 ) and its inhibition shown to reverse this effect ). Cdc25B, G2-M-phase phosphatase, its high expression is correlated with increased carcinogenesis and poor prognosis in colorectal carcinoma (Takemasa et al. 2000) . Inhibition of Cdc25B expression by small interfering RNA shown to inhibit growth of liver tumor (Yan et al. 2008) . High levels of Cdc25C, dual phosphatase is correlated with neoplastic properties of mutant p53-breast tumor cell lines (James 2006) . Structural maintenance of chromosomes 1A (SMC1A) involved in chromosome cohesion, DNA repair and is overexpressed in colorectal carcinomas (Carvalho et al. 2012) . Knock down of SMC1A expression showed inhibition of human glioma cell growth . Separase (ESPL1) is an endopeptidase reported to be overexpressed in a wide range of human cancers including mammary epithelial cells and is implicated in tumorogenesis (Zhang et al. 2008) .
Check point kinase 2 (CHEK2) is a signal transducer in ataxia telangiectasia mutated-mediated DNA damage response signaling pathway. Inhibition of CHEK2 is shown to enhance apoptotic activity of γ-irradiation and anticancer drug-induced apoptosis in a colon carcinoma model (Yu et al. 2001; Ghosh et al. 2006) . Several Chk2 inhibitors have been evaluated in phase I clinical studies (Takumi 2004) . Another important gene down-regulated by SRL, Polo like kinase 1 or PLK1 is serine/threonine kinase, an important regulator in cell cycle progression, DNA replication, mitosis and execution of cytokinesis. Overexpression of Plk1 is seen in many cancers, and its high expression in tumors is often correlated with aggressiveness and poor prognosis. Depletion in Plk1 levels is correlated with decrease in cell viability and induction of apoptosis. Plk1 inhibitors are being studied for anticancer therapy and are at different stages in clinical development (Chopra et al. 2010; Song et al. 2012) . Down-regulation of all these genes involved in cell cycle and DNA replication by SRL suggests that lectin arrests HT29 cell cycle at all the phase's viz. G1, S and G2/M leading to the growth inhibition, which supports our earlier reported results .
At 24 and 48 h, SRL altered the expression of genes involved in apoptosis pathway. Apoptosis is a programed cell death executed by two pathways namely extrinsic (Fas: FasL mediated) and intrinsic (mitochondrial mediated) pathway. Caspases are serine proteases, exist in precursor forms and get activated in response to death signals. Hence differential expression of the caspases upon any drug action will not directly affect apoptosis pathway. Whereas, differential expression of apoptosis inducing proteins like FasL and BH3 only proteins and antiapoptotic proteins will decide the cell fate. Cancer cells resist and escape apoptosis and survive by expressing antiapoptotic proteins (Bcl-2 proteins) in high levels or by suppressing the expression of pro-apoptotic proteins (Fas, FasL and BH3 only proteins). Our previous studies have deduced the detailed mechanism of SRL-induced apoptosis in colon cancer HT29 cells. SRL induces apoptosis in HT29 cells by activation of both extrinsic and intrinsic apoptosis signaling as demonstrated by the increased expression of FasL, Fass-associated death domain, truncation of BID resulting in the activation of caspases-8, -9, -3 and Poly(ADP-ribose) polymerase cleavage .
Interestingly in this study it has been observed that SRL altered expression of many genes belonging to apoptosis pathway further substantiating our earlier observation. SRL up-regulated pro-apoptotic genes like BMF, BIK and HRK at 24 h and Noxa and Sept4 at 48 h. In contrast, at late time points the only antiapoptotic gene upregulated by SRL is BIRC2. Mitochondrial pro-apoptotic proteins BMF, BIK HRK, Noxa and Sept4 initiate intrinsic-mediated apoptotic pathway by neutralizing/interacting with the apoptotic inhibitors BCL-2 and BCL-X(L) via its BH3 domain. Reports have shown that Bmf expression is sufficient to induce apoptosis (Shao and Aplin 2012) . Apoptosis induced by many of the toxins, cytokines and virus infection is mainly mediated by BIK up-regulation (Chinnadurai et al. 2008) . Aberrant methylation of HRK is correlated with its inactivation and its restoration by methyl transferase, and histone deacetylase inhibitors induce apoptosis in colorectal and gastric cancer cell lines (Obata et al. 2003) . Some anticancer drugs are known to exert cytotoxic effect in human colorectal carcinoma cell lines by induction of Noxa expression (Okumura et al. 2008) . Sept4 is shown to mediate TGF-β induced apoptosis and also mediates apoptosis in response to pro-apoptotic stimuli (Gottfried et al. 2004) .
At 48 h, another important apoptosis inducing gene up-regulated by SRL is FasL whose expression is also shown earlier at protein level. FasLG is a transmembrane protein that triggers extrinsic apoptosis following ligation to its receptor Fas (CD95/APO-1). Up-regulation of FasL expression has been implicated in colon carcinogenesis (Bennett et al. 2001) . In contrast, in vivo experiments have shown that gene transfer of FasL inhibited the tumor growth (Arai et al. 1997) . SRL down-regulated p53-inducible protein with a death domain (PIDD), scaffold protein implicated in DNA damage response and PTHR2 (Bit1), mitochondrial protein implicated in regulation of apoptosis (Jan et al. 2004 ) at 48 h.
In conclusion, SRL increased expression of transcripts of many pro-apoptotic genes like FasL, BMF, BIK HRK, Noxa and Sept4 and antiapoptotic gene BIRC2 at late time points further supporting the observed induction of cellular apoptosis in colon cancer HT29 cells.
Changes in miRNA expression at early time point by SRL were also studied along with mRNA expression. Changes in miRNA expression have been described in various types of cancers that have significance in regulating the expression of different genes. Interestingly, hsa-miR-19b shows highest level of up-regulation in the treated samples in all the time points except for 4 h. miR-19b belongs to the miR-17-92 cluster family and has been implicated in the regulation of self-renewal and proliferation of gastric cancer stem cells where as it is down-regulated during the differentiation process (Wu et al. 2013) . Interestingly the validated gene targets, e.g. SOCS1 and BCL2L11 of miR-19b detected by microarray analysis were found to be up-regulated rather than being down-regulated. However, both these genes are also targeted by miR-155, which is down-regulated by SRL at 8 and 12 h. miR-155 down-regulated by SRL is reported to be elevated in a wide array of cancers and plays a key role in lymphocyte activation in vivo (Thai et al. 2007 ). Previous studies have demonstrated downregulation of miR-155 to produce an inhibitory effect on growth of cancer cells (Lu et al. 2009 ) by targeting tumor suppressor genes. Our analysis revealed that down-regulation of miR-155 by SRL results in the up-regulation 20 and 28 gene targets at 8 and 12 h, respectively. miR-155 and miR-494, which are down-regulated by 3-4 fold at 8 and 12 h, are known to be regulated by activator protein 1 (AP1) containing c-Jun as a heterodimeric protein (Ohdaira et al. 2010) . The data are in contrast to our gene expression microarrays, which show ∼3 fold up-regulation of c-JUN at 8 and 12 h expecting the up-regulation of miR-155 and miR-494. Interestingly, the western blotting data for monitoring the expression of cJUN falls in line with down-regulation of cJUN and also their targets miR-155 and miR-494. The data suggest a different role of SRL in the regulation of these oncogenic miRNAs. Changes in miRNA expression at late time points by SRL was also studied using miRNA microarray. hsa-miR-7 is one of the miRNAs, which showed a marked up-regulation by 25-fold at 24 h. The gene expression study revealed one of its target genes, MCM2 to be downregulated by 3.5-fold. Mini chromosome maintenance proteins (MCM) are essential components of DNA replication and cell proliferation and have been correlated with cell proliferation state in colon cancer (Giaginis et al. 2009 ). Overexpression of miR-7 has been previously reported to suppress proliferation and induce apoptosis in nonsmall cell lung cancer A549 cells (Xiong et al. 2011 ) by down-regulating BCL2. PLK1 is an example of another cell cycle gene, which shows 5-fold down-regulation. The gene is a target of miR-30a, which is upregulated in treated cells by ∼3-fold. PLK1 plays a key role in mitosis and is involved in the maintenance of genomic stability and it has been identified a potential cancer therapy target.
Interestingly at 48 h, hsa-miR-630 showed robust up-regulation (42-fold) upon SRL treatment. Correspondingly, one of its target genes CASP3 was down-regulated by 2-fold. Previous studies have shown that overexpression of miR-630 induces apoptosis in pancreatic cancer cells (Farhana et al. 2013 ) and has also been demonstrated to promote apoptosis in nonsmall cell lung cancer (Galluzzi et al. 2010) . Taken together, the results suggest a global role of miR-630 in the induction of apoptosis in various types of cancers and also a possible mechanism of SRL action leading to apoptosis.
Gene expression microarray data were validated by both qRealtime-PCR and western blotting studies. Overall, there was good correlation between microarray and qRT-PCR data with both the results showing similar trends. For example, c-JUN showed maximal upregulation at 2 and 4 h (4.5-to 6-fold, respectively) similar to the microarray results. We also validated the lectin-induced differentially regulated key genes from each of the significantly affected pathway by western blotting analysis. As mentioned earlier, microarray and qRT-PCR analysis revealed the up-regulation of the transcription factor, c-JUN involved in the MAPK pathway at early time points, however, its expression at the protein level was not falling in line with the observed gene expression data. As the expression of c-JUN is implicated both in cell proliferation and in induction of apoptosis (Wisdom et al. 1999) , it is likely that at down-regulation of c-JUN observed at protein expression level is likely to induce the observed inhibitory effect of SRL on HT29 cells. AP1, a transcription factor containing c-JUN protein, implicated in cellular differentiation, proliferation and apoptosis. Activation of AP1 is linked to growth of colorectal cancer and the gene transfer of dominant-negative mutant of c-Jun resulted in the specific obstruction of AP-1 and in turn prevented colon cancer growth (Suto et al. 2004) . Hence the down-regulation of c-JUN by SRL is likely to inhibit the activation of AP1 and can be implicated for the observed inhibitory effect on HT29 cells. Western blotting studies revealed the reduced expression levels of PLK1 involved in cell cycle pathway at late time points, which is also shown to be down-regulated at mRNA level following SRL treatment. Cyclin D1, an important cyclin, required to drive the cell cycle at G0/ G1 phase and is partially down-regulated by lectin at 48 h. Hence it is likely that SRL induces its observed growth inhibitory effect by arresting cells at G0/G1 phase. However, microarray analysis showed no change in cyclin D1 expression both at 24 and 48 h. DNA replication protein RPA4 selected from DNA replication pathway was shown to be up-regulated at mRNA level but at protein expression level no changes were seen compared with control HT29 cells.
Overall the protein expression levels of down-regulated genes are in line with observed microarray data. It should be mentioned that the expression of some genes like c-JUN and RPA4 are slightly different at protein and gene level. This is not surprising as not all the genes are necessarily translated to functional proteins (Al Moustafa et al. 2002; Chuaqui et al. 2002) .
In conclusion, SRL affects multiple signaling pathways in cancer cells with early effects on cell proliferation pathways associated with MAPK and c-JUN, followed by miRNA-associated cell activity and apoptosis. This provides insight information into the molecular mechanism of the anticancer activity of this fungal lectin. Ltd., USA, fetal bovine serum (FBS), US origin was from Gibco Invitrogen, Calcein AM fluorescent dye was from Invitrogen Eugene, Oregon. Absolutely RNA miRNA Kit, RNA ScreenTape Low Input Quick Amp labeling kit (one-color), miRNA complete labeling and Hyb kit, Brilliant III ultrafast SYBR ® Green QRT-PCR master mix were obtained from Agilent Technologies (La Jolla, CA, USA). PVDF membrane was procured from Millipore, MA, USA. Antibodies to c-JUN, PLK1 and Cyclin D1 were procured from Cell Signalling Technologies (Beverly, MA, USA). RPA4 antibody is procured from Abcam (Cambridge, MA, USA). Species-specific HRP-labeled secondary antibodies were procured from Bio-Rad (Hercules, CA, USA). Chemiluminescence kit was procured from Bio-Rad Laboratories Inc.. SRL is known to lose its hemagglutination activity at 70°C. Hence Denatured SRL (DSRL) was prepared by heat inactivation. Briefly, lectin was incubated at 70°C for 5 min and tested for its loss of agglutinating activity by hemagglutination assay and used for testing the effect. Bovine asialo mucin (BAM) was prepared by acid hydrolysis of bovine submaxillary mucin, as described by Spiro (1960) . In brief, BM was dissolved in 0.05 M H 2 SO 4 containing 0.15 M NaCl and the mixture was incubated at 80°C for 1 h. Incubated samples were then centrifuged at 4500g for 30 min at room temperature. Supernatant obtained was dialyzed against distilled water extensively and was lyophilized and used for the inhibition studies.
Materials and methods
Cell culture
The human colon cancer HT29 cells were obtained from the European Cell Culture Collection via the Public Health Laboratory Service (Porton Down, Wiltshire, UK). HT29 cells were cultured in DMEM supplemented with 10% FBS, 100 units/mL penicillin, 100 µg/mL streptomycin (complete DMEM) at 37°C in 5% CO 2 . were maintained to ensure the absence of contaminations. The fold change expression levels of each gene were calculated after normalization of GAPDH expression levels. Fold change expression ≥1 was considered up-regulation and ≤1 was considered down-regulation. This figure is available in black and white in print and in color at Glycobiology online.
ester (AM) method. Briefly, sub-confluent HT29 cells were seeded at 4 × 10 4 cells/mL in 96-well plates in DMEM containing 10% FBS (complete medium) for 48 h. The medium was replaced with serum-free DMEM containing 0.5% BSA (w/v), and the cells were incubated with 20 µg/mL of SRL for 2, 4, 8, 12, 24 and 48 h at 37°C. Effect of DSRL and TBS on HT29 cells were also studied for 24 and 48 h. After incubation for the specified time point, the cells were trypsinized and labeled with 10 µM calcein AM at 37°C for 30 min in a CO 2 incubator, lysed with 100 µL lysis buffer (50 mM Tris-HCl, pH 6.8, with 5% SDS and 2% mercaptoethanol). The fluorescent intensity was read using Tecan M200pro microplate reader with an excitation wave length of 485 nm and an emission wave length of 535 nm. To observe effects of competing glycoprotein, SRL was pre-incubated with 100 µg/mL of BAM and BM, for 1 h before they were treated with cells and then processed as mentioned above. Percentage viable cell number was calculated, with respect to controls considered as 100%.
Preparation of samples for RNA isolation following SRL treatment HT29 cells were treated without and with SRL at different time points for isolation of RNA required for microarray analysis as follows: cells were seeded at a concentration of 0.8 × 10 6 cells in T25 flask (5 mL) and incubated for 48 h in DMEM containing 10% FBS (complete media). After incubation cells were treated without (Control) and with SRL (20 µg/ mL) (Treated) in DMEM media containing 0.5% BSA (incomplete media) and were incubated for different time points (2, 4, 8, 12, 24 , and 48 h). Following incubation for specified time point, the spent media were removed and the cells were washed twice with PBS and released using a cell scraper. The harvested cells in PBS (2 mL) were transferred to sterile DEPC-treated centrifuge tubes and washed with PBS, centrifuged at 1500 rpm at 4°C and the cell pellet was used to isolate total RNA or stored at −80°C for further studies. Cells were grown in three T25 flasks in biological replicates for all the time points (control and treated). One million cells from each time point were used for RNA isolation.
Preparation of RNA
Total RNA was extracted from treated and control HT29 cells using the Agilent Absolutely RNA miRNA Kit. Both mRNA and miRNA were quantitatively recovered using this kit, allowing gene expression studies of both mRNA and miRNA from the same sample.
RNA quality control and testing
The RNA integrity number (RIN) values indicate the quality of isolated RNA, which was determined on the Agilent 2200 TapeStation system. In brief, a volume of 1 µL of RNA ScreenTape ladder was aliquoted into the first well of an optical tube strips (8× Strip) followed by the addition of 1 µL of total RNA to rest of the wells and mixed with 5 µL of sample buffer. The sample was briefly mixed by vortexing, denatured at 72°C for 5 min and cooled at 4°C for 5 min and centrifuged to collect the samples. The samples were then placed in the 2200 TapeStation system, analyzed and the sample with RIN values greater than seven (good quality RNA) were used for microarray analysis.
Preparation of samples for mRNA analysis
Twenty-five nanograms of RNA from control and treated samples for each time point were labeled with Cy3 dye using Low Input Quick Amp Labeling Kit in three technical replicates. Gene expression microarray analysis on all the replicates were performed using the Agilent SurePrint G3 Human GE 8X60K V2 Microarray and an Agilent SureScan Microarray scanner. The gene expression data were extracted using Agilent Feature Extraction Software (11.5 .1.1) and analyzed using Agilent GeneSpring GX (12.6.1). In both mRNA and miRNA analyses, transcripts exhibiting P ≤ 0.05 and fold changes ≥2 two were considered to be differentially expressed.
Preparation of samples for miRNA analysis
One hundred nanograms of miRNA were labeled with Cy3 dye using Agilent's miRNA Complete Labeling and Hyb Kit. The labeling was performed from control and treated samples for each time point in three technical replicates. miRNA microarray analysis on all the replicates were performed using the Agilent SurePrint G3 Human v16 miRNA 8X60K Microarray kit and Agilent SureScan Microarray scanner. The miRNA data were extracted using Feature Extraction and analyzed using Agilent GeneSpring GX (12.6.1). The validated targets of miRNAs were identified using miRWalk (Dweep et al. 2011) .
Primer designing and qReal-time-PCR assay
RNA was extracted from the cell pellets as described earlier. All the primers used in the study were designed using Beacon Designer™ (Premier Biosoft). The list of differentially regulated genes used for qRT-PCR validation is provided in Table VII . One-step RT-PCR was performed by using Brilliant III ultrafast SYBR ® Green QRT-PCR master mix. The 20 µL reaction contained 10 µL of master mix, 3 µL of forward and reverse primers (150 nM), 1 µL of RT/RNase block, 0.2 µL of DTT and 16.7 ng of total RNA per reaction. The amplifications were performed in 96 well plates using Mx3005P qPCR instrument (Agilent Technologies). After the reverse transcription step at 50°C for 5 min, denaturation was performed at 95°C for 3 min, followed by 40 cycles of 95°C for 10 s and annealing/extension for 20 s (50-60°C depending on the primer pairs). No template controls (NTCs) were maintained to ensure the absence of contaminations. Each reaction was performed in triplicates, and the average Ct values were considered for calculation. The fold change expression levels of each gene were calculated after normalization of GAPDH expression levels. Fold change expression ≥1 was considered up-regulation and ≤1 was considered down-regulation.
Statistical analysis
Microarray data and pathway analysis The microarray data were analyzed for gene expression by mRNA and miRNA using the Gene Expression and miRNA workflow in GeneSpring GX 12.6.1, respectively. Default flag settings were used to make the detection calls. Signal intensities for each probe were normalized to 75th percentile without baseline transformation for gene expression analysis. No normalization and baseline transformation was performed for miRNA analysis. Differential gene and miRNA expression analysis was performed using the "Filter on Volcano Plot" option in GeneSpring. The analysis was carried out using a T-test unpaired statistical method with Benjamini Hochberg FDR method; P-values were computed asymptotically. Pathway analysis was carried out using the Pathway Analysis Module in GeneSpring 12.6.1. The DEG entity list for each time point (P ≤ 0.05 and fold change ≥2.0) was selected for pathway analysis. Curated pathways from the WikiPathways portal (http://www. wikipathways.org) were imported into GeneSpring and used for pathway analysis. The acquired Gene expression microarray and miRNA microarray data have been deposited at ArrayExpress (www.ebi.ac. uk/arrayexpress) under the accession numbers E-MTAB-3002 for
